EGFR C797S介导的奥希替尼耐药肺癌对一代EGFR抑制剂短暂应答后获得T790M/C797S
该研究探讨EGFR突变肺癌经奥希替尼耐药后出现C797S时,一代可逆EGFR抑制剂(吉非替尼或厄洛替尼)的疗效及后续耐药机制。临床前模型显示L858R/C797S背景经吉非替尼暴露后优先出现L858R/T790M/C797S。一例delE746_T751insV患者奥希替尼持续应答10个月后出现C797S,厄洛替尼应答4个月后进展,液体活检发现T790M与C797S顺式共存。
要点
- EGFR C797S是奥希替尼获得性耐药机制之一。
- 一代可逆EGFR抑制剂对C797S肿瘤仅短暂应答。
- 治疗中可出现T790M与C797S顺式共存导致再耐药。
核心结论
- EGFR敏感突变肺癌可通过获得C797S对奥希替尼耐药,一代可逆EGFR抑制剂仅带来短暂应答。
- 临床前与临床标本均提示肿瘤可演化出EGFR T790M/C797S,支持探索联合治疗以延迟或预防在靶耐药。
研究设计与样本
- 临床前研究采用N-乙基-N-亚硝基脲诱变在EGFR L858R/C797S背景中评估可逆EGFR抑制剂的耐药谱。
- 回顾性分析一例EGFR delE746_T751insV肺腺癌患者一线奥希替尼、二线厄洛替尼治疗及液体活检结果。
主要发现
- 在EGFR L858R/C797S背景中经N-乙基-N-亚硝基脲诱变并给予吉非替尼后,优先出现EGFR L858R/T790M/C797S细胞。
- 一例EGFR delE746_T751insV患者一线奥希替尼持续应答10个月后获得EGFR C797S。
- 该患者二线厄洛替尼应答4个月后疾病进展,液体活检显示delE746_T751insV与T790M及C797S顺式共存。
临床怎么用
- 对奥希替尼耐药且检出EGFR C797S的患者,可考虑一代可逆EGFR抑制剂但需预期应答短暂。
- 治疗中应监测T790M/C797S等在靶耐药演化,并考虑联合策略以延长获益。
局限性
- 临床证据仅来自单例回顾性分析,结论的普遍性有限。
- 临床前模型基于特定突变背景(L858R/C797S)与吉非替尼,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation EGFR inhibitor are evolving. Whether durable control of subsequently osimertinib-resistant NSCLC with the EGFR-sensitizing mutation (SM)/C797S is possible with first-generation EGFR inhibitors (such as gefitinib or erlotinib) remains underreported, as does the resultant acquired resistance profile. METHODS: We used N-ethyl-N-nitrosourea mutagenesis to determine the profile of EGFR SM/C797S preclinical models exposed to reversible EGFR inhibitors. In addition, we retrospectively probed a case of EGFR SM lung adenocarcinoma treated with first-line osimertinib, followed by second-line erlotinib in the setting of EGFR SM/C797S. RESULTS: Use of N-ethyl-N-nitrosourea mutagenesis against the background of EGFR L858R/C797S in conjunction with administration of gefitinib revealed preferential outgrowth of cells with EGFR L858R/T790M/C797S. A patient with EGFR delE746_T751insV NSCLC was treated with osimertinib with sustained response for 10 months before acquiring EGFR C797S. The patient was subsequently treated with erlotinib, with response for a period of 4 months, but disease progression ensued. Liquid biopsy disclosed EGFR delE746_T751insV with T790M and C797S present in cis. CONCLUSION: EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation. In this clinical scenario, the tumor may respond transiently to reversible first-generation EGFR inhibitors (gefitinib or erlotinib), but evolving mechanisms of on-target resistance-in clinical specimens and preclinical systems-indicate that EGFR C797S along with EGFR T790M can evolve. This report adds to the growing understanding of tumor evolution or adaptability to sequential EGFR inhibition and augments support for exploring combination therapies to delay or prevent on-target resistance.
引用
- Rangachari D, To C, Shpilsky JE, et al. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thorac Oncol. 2019. PMID: 31377341. doi:10.1016/j.jtho.2019.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。